Myriad Genetics, Inc.
MYGN
F
|
$18.515
0.03%
0.03%
490K
|
Health Technology
(0.0% 1d) (-16.2% 1m) (-14.8% 1y) (0.0% 2d) (0.0% 3d) (-2.8% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,675,204,891
http://www.myriad.com
Sec Filling | Patents | 2700 employees
(US) Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
molecular diagnostics genetic diagnostics information technology
add to watch list Paper trade email alert is off
Press-releases
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 1.93%
H: 1.47%
C: -2.05%
health genesight
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
prequel positive for study
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.44%
H: 3.39%
C: 2.5%
depression genesight research for
Companion Diagnostics Market Worth $13.6 billion | MarketsandMarkets™
Published: 2024-04-05 (Crawled : 14:30) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -1.7%
H: 2.39%
C: 1.62%
A | $132.73 0.22% 0.0% 1.3M
|
Health Technology
|
| O: 2.01%
H: 0.92%
C: -0.04%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -0.64%
H: 2.19%
C: 0.85%
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: -0.75%
H: 3.52%
C: 2.16%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.31%
H: 2.54%
C: 1.49%
companion diagnostics market
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Published: 2024-03-22 (Crawled : 02:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.13%
H: 0.69%
C: -0.4%
patent disease granted molecular
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.72%
H: 1.43%
C: -0.45%
sneakpeek patent device granted
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -1.06%
H: 2.15%
C: -7.05%
million revenue financial
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Published: 2024-02-27 (Crawled : 14:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.31%
H: 3.26%
C: 2.17%
japan hospital cancer
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Published: 2024-02-21 (Crawled : 21:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.35%
H: 2.35%
C: 0.48%
year financial results
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -0.68%
H: 1.15%
C: -0.77%
health medical
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 1070000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT | News P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10